Drugs and the FDA: Safety, Efficacy, and the Public''s Trust | Agenda Bookshop Skip to content
Online orders placed from 19/12 onward will not arrive in time for Christmas.
Online orders placed from 19/12 onward will not arrive in time for Christmas.
A01=Mikkael A. Sekeres
Age Group_Uncategorized
Age Group_Uncategorized
Author_Mikkael A. Sekeres
automatic-update
Category1=Non-Fiction
Category=LNTM
COP=United States
Delivery_Delivery within 10-20 working days
Language_English
PA=Available
Price_€20 to €50
PS=Active
softlaunch

Drugs and the FDA: Safety, Efficacy, and the Public''s Trust

English

By (author): Mikkael A. Sekeres

How the FDA was shaped by public health crises and patient advocacy, told against a background of the contentious hearings on the breast cancer drug Avastin.

Food and Drug Administration approval for COVID-19 vaccines and the controversial Alzheimers drug Aduhelm made headlines, but few of us know much about how the agency does its work. Why is the FDA the ultimate US authority on a drugs safety and efficacy? In Drugs and the FDA, Mikkael Sekeresa leading oncologist and former chair of the FDAs cancer drug advisory committeetells the story of how the FDA became the most trusted regulatory agency in the world. It took a series of tragedies and health crises, as well as patient advocacy, for the government to take responsibility for ensuring the efficacy and safety of drugs and medical devices. 

Before the FDA existed, drug makers could hawk any potion, claim treatment of any ailment, and make any promise on a label. But then, throughout the twentieth century, the government was forced to take action when children were poisoned by contaminated diphtheria and smallpox vaccines, an early antibiotic contained antifreeze, a drug prescribed for morning sickness in pregnancy caused babies to be born disfigured, and access to AIDS drugs was limited to a few clinical trials while thousands died. Sekeres describes all these events against the backdrop of the contentious 2011 hearings on the breast cancer drug Avastin, in which he participated as a panel member. The Avastin hearings, he says, put to the test a century of the FDAs evolution, demonstrating how its system of checks and balances worksor doesnt work. See more
Current price €32.29
Original price €33.99
Save 5%
A01=Mikkael A. SekeresAge Group_UncategorizedAuthor_Mikkael A. Sekeresautomatic-updateCategory1=Non-FictionCategory=LNTMCOP=United StatesDelivery_Delivery within 10-20 working daysLanguage_EnglishPA=AvailablePrice_€20 to €50PS=Activesoftlaunch
Delivery/Collection within 10-20 working days
Product Details
  • Dimensions: 152 x 229mm
  • Publication Date: 06 Feb 2024
  • Publisher: MIT Press Ltd
  • Publication City/Country: United States
  • Language: English
  • ISBN13: 9780262548397

About Mikkael A. Sekeres

Mikkael A. Sekeres is Professor of Medicine and Chief of the Division of Hematology at the Sylvester Comprehensive Cancer Center University of Miami Miller School of Medicine and former Chair of the Oncologic Drugs Advisory Committee of the FDA. A regular contributor to the Well section of the New York Times he is the author of When Blood Breaks Down: Life Lessons from Leukemia (MIT Press).

Customer Reviews

Be the first to write a review
0%
(0)
0%
(0)
0%
(0)
0%
(0)
0%
(0)
We use cookies to ensure that we give you the best experience on our website. If you continue we'll assume that you are understand this. Learn more
Accept